| Literature DB >> 24909985 |
Nesrine I Affara1, Brian Ruffell1,2,3, Terry R Medler2, Andrew J Gunderson2, Magnus Johansson1, Sophia Bornstein4, Emily Bergsland5,6, Martin Steinhoff7, Yijin Li8, Qian Gong8, Yan Ma8, Jane F Wiesen1,2, Melissa H Wong2,9,3, Molly Kulesz-Martin2,9,3, Bryan Irving8, Lisa M Coussens1,6,2,3.
Abstract
B cells foster squamous cell carcinoma (SCC) development through deposition of immunoglobulin-containing immune complexes in premalignant tissue and Fcγ receptor-dependent activation of myeloid cells. Because human SCCs of the vulva and head and neck exhibited hallmarks of B cell infiltration, we examined B cell-deficient mice and found reduced support for SCC growth. Although ineffective as a single agent, treatment of mice bearing preexisting SCCs with B cell-depleting αCD20 monoclonal antibodies improved response to platinum- and Taxol-based chemotherapy. Improved chemoresponsiveness was dependent on altered chemokine expression by macrophages that promoted tumor infiltration of activated CD8(+) lymphocytes via CCR5-dependent mechanisms. These data reveal that B cells, and the downstream myeloid-based pathways they regulate, represent tractable targets for anticancer therapy in select tumors.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24909985 PMCID: PMC4063283 DOI: 10.1016/j.ccr.2014.04.026
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743